Future News: If You Have Money, Don’t Be In Trouble

Chapter 567 Take Down Kano Biological Company

The M&A team sent by Luo Dagui landed at Kyoto International Airport at 11:35 noon. The team was led by a young lawyer who was only 37 or 18 years old. His name was Fang Zhengyi. He graduated from the University of Political Science and Law with a Ph.D. Years, practical experience and solid theoretical knowledge of industry law.

Besides Dongfang Luyao, Cao Meng was the one who picked her up at the airport.

Cao Meng, as the representative of Ye Qiusheng, expressed a warm welcome to Fang Zhengyi and his party of six, and at the same time conveyed to them the boss's instructions, that is, Kano Biotech must be fully acquired, and the sooner the better.

Then, they went to Kano Bioengineering Technology Co., Ltd. located in the southeast of the Fifth Ring Road. Along the way, they had a simple meal at a restaurant that looked good.

When they arrived at the gate of Kano Biology, there were already several people waiting for them in front of the gate.

After breaking up with Ye Qiusheng yesterday afternoon, Dongfang Luyao, with the assistance of Chen Hao, collected all the public information of Jingdu Kano Biology on the Internet and conducted targeted research.

The chairman of Kano Biotech is Chen Zijie, a doctor of returnees. He worked in a famous European biological laboratory for five years and mastered many bioengineering technologies that could be called the world's leading at that time. However, he has fallen behind now.

In 2009, Chen Zijie brought 1 million US dollars back to China, and founded Kano Biotechnology with a few like-minded friends.

In the past 9 years, Kano Bio has experienced four financing expansions.

Now the total share capital is 156 million shares, Chen Zijie holds 20.09% of the shares, Chen Zijie’s wife Li Fengjiao holds 4.51% of the shares, other founders and executives of the company hold 7.33% of the shares, a biological laboratory of Shuimu University holds 4.78% of the shares, and Modu Nanfang Pharmaceutical holds 4.51% of the shares. 6.42% of the shares, and the remaining shares are divided by four financial investment companies, ranging from 15% to 6%.

The company's shareholding structure is relatively complicated, and it is not listed.

Net worth unknown, market value unknown.

Last year, Kano Bio's turnover exceeded 700 million yuan, and its net profit was more than 67 million yuan. However, the growth rate of net profit fell by 21% compared with last year, and it was only enough to repay part of the interest on the loan. The company seems to be in trouble.

This morning, Dongfang Luyao called the secretary of the chairman of the company to discuss cooperation matters in the name of Jingdu Xinrou Financial Consulting Company, and faxed the company a business application letter stamped with Xinrou Financial's official seal.

In other words, if this matter drags on for another day, Concubine Yunye should come forward, but it's a pity that Concubine Yunye is not a member of Xinrou Finance this morning, and Yu Xinrou does not have the qualifications.

Emotional intelligence and knowledge of negotiations.

An hour later, Dongfang Luyao received a call back from Kano Bio.

Said: At 2 o'clock in the afternoon, Mr. Chen Zijie, the chairman, and Ms. Li Fengjiao, the president, are waiting for you in the company.

Only then did Kano Biology's senior executives welcome the scene in front of the door.

The specific reason why Kano Bio is full of expectations for Xinrou Finance has a lot to do with their poor financial status and the registered capital of "Xinrou Finance" they found on the official website of the State Administration for Market Regulation is as high as 10 billion yuan.

The details will not be repeated here.

After getting off the car, the two sides shook hands and introduced each other.

Those who welcomed Dongfang Luyao and his party were Chairman Secretary Wang Shiyu, two vice presidents and several staff members.

Wang Shiyu is a man in his thirties. This is the narrowness of his wife being the president of the company. It is impossible to match her husband with a beautiful secretary.

A dozen people first walked around the park and visited the production workshop and laboratory building.

This motion was proposed by Fang Zhengyi's lawyer temporarily. Of course, the owner did not allow them to enter the laboratory.

However, they still saw the scale of this laboratory building. Judging from the advanced level of equipment, it should be in a leading position in China.

On the way to participate, President Li Fengjiao, who was waiting in the conference room, rushed over. She showed great enthusiasm for Dongfang Luyao and her party. Although this President Li is ordinary in appearance, he talks humorously and has strong professional technical knowledge. Like a down-to-earth capable woman.

It's just a pity that the market is not something you can play with professional skills.

Around three o'clock, a group of more than a dozen people returned to a conference room in the administrative building.

Chen Zijie, chairman of Kano Biotech, greeted him in front of the meeting room.

After another round of greetings and introductions, the two parties sat facing each other.

The first negotiation for the acquisition of Kano Biotech officially started.

During the communication, there was a huge deviation in the cognition of the two sides.

Regarding Kano Bio, Chen Zijie hopes to take part of the shares to obtain preferential financing from Xinrou Finance.

Xinrou Financial is not interested in obtaining part of the shares through financing. Fang Zhengyi proposed a wholly-owned acquisition of Kano Biotech, and is willing to purchase at a premium at the appraisal price of the professional appraisal department.

Negotiations stalled for a while.

Although Fangzheng's team only had contact with the acquisition for a short dozen hours, they basically collected all the information they should have on Kano Bio.

Due to unconventional construction of infrastructure and purchase of expensive advanced instruments, Kano Biotech faced a huge mortgage due and was unable to repay

risks of.

Although it is not at the end of the mountain, it also shows a strong fatigue, and the subsequent development is weak. If there is no financial support, bankruptcy will not be far away.

The four financing companies saw that the development of Kano Biotech was hindered. They had long thought of selling the shares of Kano Biotech, but they have not yet found a suitable buyer to take over the offer. It is not a big problem to acquire the shares of these four financing companies. The key is that Chen Zijie and Li Fengjiao hold nearly 25% of Class A shares with absolute right to speak.

They are the crux of Kano's changing hands.

As for the shares held by Shuimu University and Nanfang Pharmaceutical, it is also very easy to buy them out. As long as there is pressure from above, it is not impossible to sell them at a fair price. These two are g companies and public institutions.

Another round of tongue-in-cheek talk.

Fang Zhengyi mercilessly exposed the economic difficulties faced by Kano Biotech. At the same time, he pointed out that Kano Pharmaceuticals is on the verge of life and death, and if it takes a step back, the sea and the sky will be brighter. If it is tough, the final outcome can only be bankruptcy and liquidation. The assets of the company founders will be wiped out.

In this regard, the company executives who participated in the negotiation were all moved.

In their speech, they began to tend to sell the company and take the money and leave.

Human selfishness played the most primitive role at this moment.

At around five o'clock in the evening, under tremendous psychological pressure, Chen Zijie expressed that he would discuss with the company's founders and shareholders.

Discussion temporarily adjourned.

Kano Biology prepared work lunches for their group of eight and three drivers.

After they finished their minimal work dinner, Chen Zijie and his party also returned to the meeting room.

Chen Zijie got straight to the point: "We both need to find an appraisal company. If the appraisal report is not too different in the end, the asset appraisal price will be averaged, and the purchase price will be a 20% premium to the average value. It will be paid in one lump sum, and installments will not be accepted."

The tone is very strong, but the look is stern.

Fangzheng smiled, and the matter was settled.

"Chairman Chen, this premium is a bit too much, we can only give 8%, which is very sincere."

It was another round of bargaining between the two sides.

In the end, the premium ratio was set at 14%, and the two sides made concessions to each other.

As a result, the first round of intentional negotiation has come to an end.

Next, Founder's six-person team still has a lot of work to do, not only asset appraisal and financial audit, but also labor disputes, debt disputes and other matters that need to be clarified, including overdue interest and fines on bank loans.

Other shareholders also need to discuss one by one.

The work is huge and cumbersome, and it takes time to kill it.